The RECOVER open label trial demonstrated positive results for brilaroxazine for schizophrenia.
Laxminarayan Bhat, PhD
Advertisement
Dr Bhat is founder, president, and chief executive officer of
Reviva Pharmaceuticals Holdings Inc.
Articles by Laxminarayan Bhat, PhD
Advertisement
Latest Updated Articles
Open Label Phase 3 Study of Brilaroxazine for Schizophrenia Shows Efficacy, TolerabilityPublished: June 2nd 2025 | Updated:
Advertisement
Advertisement
Trending on Psychiatric Times
1
Improving Outcomes in Schizophrenia With Long-Acting Injectables: Insights from the Southern Florida Psychiatry Conference
2
Prescription Digital Therapeutics: Transforming Health Care Delivery
3
The Future of ADHD Care: Redefining Adult Diagnosis and Treatment
4
Benefits of Long-Acting Injectable Antipsychotics: An Overview From Southern Florida Psychiatry Conference
5
